Five years after its formation, the Clinical and Translational Science Award (CTSA) at the Univeristy of North Carolina at Chapel Hill (UNC), the North Carolina Translational and Clinical Sciences Institute (NC TraCS), has become the integrated, campus-wide home for clinical and translational research at UNC. The overall goal of this U54 Cooperative Agreement application is to combine the research strengths, resources and opportunities at UNC and new partner, RTI International (RTI), to build on the foundation established in the CTSA's last five years. NC TraCS .will work to improve human health by accelerating clinical and translational research from health science discovery to dissemination to patients and communities. NC TraCS will strive to overcome the well-documented barriers to the effective, sustained translation of research discovery along the translational research continuum by improving efficiency, training a research workforce and exporting successful, validated methods developed in NC TraCS to other CTSA institutions and the public. The proposed CTSA will specifically (1) amplify a thriving CTSA program to the point that it supports the full spectrum of clinical and translational research; (2) leverage CTSA resources and institutional strengths to create a critical, sustained focus on three strategic initiatives: (a) next-generation technologies to transform the very nature of clinical research and practice, (b) new paradigms and resources to accelerate drug development, and (c) robust comparative effectiveness research studies to provide definitive evidence of the benefits and harms of tests and treatments; and (3) train, support and incentivize the next generation of clinical and translational science researchers. These goals will be accomplished by three resources, six services, integrated and streamlined from the original 11, and the three strategic initiatives. UNC and RTI now have a unique set of research and training resources to support the full range of clinical and translational research, from basic science to clinical application to policy change. NC TraCS will leverage the opportunity of this CTSA application to garner >$60 million dollars in matching institutional support to extend our capabilities to meet the three aims. In partnership with RTI, NC TraCS will take advantage of the resources it has created and nourished during the past five years to quickly and effectively bring the fruits of research to patients across the state, as well as nationally through the CTSA Consortium.

Public Health Relevance

Researchers, clinicians and health policy experts have long lamented the well-documented lag between basic science discoveries and when those discoveries reach patients to treat them and make their lives better. The proposed UNC-RTI partnership in cooperation with the CTSA Consortium will help to ensure that patients will more quickly and effectively benefit from the results of biomedical research.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
4UL1TR001111-04
Application #
9064891
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Wilde, David B
Project Start
2013-09-26
Project End
2018-04-30
Budget Start
2016-05-01
Budget End
2017-04-30
Support Year
4
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Mellin, Juliann M; Alagapan, Sankaraleengam; Lustenberger, Caroline et al. (2018) Randomized trial of transcranial alternating current stimulation for treatment of auditory hallucinations in schizophrenia. Eur Psychiatry 51:25-33
Gilchrist, Kristin H; Hegarty-Craver, Meghan; Christian, Robert B et al. (2018) Automated Detection of Repetitive Motor Behaviors as an Outcome Measurement in Intellectual and Developmental Disabilities. J Autism Dev Disord 48:1458-1466
Khalili, Mandana; Shuhart, Margaret C; Lombardero, Manuel et al. (2018) Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Diabetes Care 41:1251-1259
Shah, Hetal S; Morieri, Mario Luca; Marcovina, Santica M et al. (2018) Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. Diabetes Care 41:348-355
Williams, Grant R; Deal, Allison M; Shachar, Shlomit Strulov et al. (2018) The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Cancer Chemother Pharmacol 81:413-417
Whitman, Nathan A; Lin, Zhi-Wei; DiProspero, Thomas J et al. (2018) Screening Estrogen Receptor Modulators in a Paper-Based Breast Cancer Model. Anal Chem 90:11981-11988
Kinlaw, Alan C; Jonsson Funk, Michele; Conover, Mitchell M et al. (2018) Impact of New Medications and $4 Generic Programs on Overactive Bladder Treatment Among Older Adults in the United States, 2000-2015. Med Care 56:162-170
Lund, Jennifer L; Sanoff, Hanna K; Peacock Hinton, Sharon et al. (2018) Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States. Cancer Epidemiol Biomarkers Prev 27:41-49
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Morieri, Mario Luca; Gao, He; Pigeyre, Marie et al. (2018) Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. Diabetes Care 41:2404-2413

Showing the most recent 10 out of 656 publications